European Journal of Contraception and Reproductive Health Care最新文献_第6页

Effects of E4/DRSP on self-reported physical and emotional premenstrual and menstrual symptoms: data from the phase 3 clinical trial in Europe and Russia. E4/DRSP对自我报告的经前和经期生理和情绪症状的影响：来自欧洲和俄罗斯第三阶段临床试验的数据。

IF 1.9 4区医学

European Journal of Contraception and Reproductive Health Care Pub Date : 2024-08-01 Epub Date: 2024-06-21 DOI: 10.1080/13625187.2024.2359117

Johannes Bitzer, Céline Bouchard, János Zatik, Steven Weyers, Terhi Piltonen, Larisa Suturina, Inna Apolikhina, Kristina Gemzell-Danielsson, Maud Jost, Mitchell D Creinin, Jean-Michel Foidart

{"title":"Effects of E4/DRSP on self-reported physical and emotional premenstrual and menstrual symptoms: data from the phase 3 clinical trial in Europe and Russia.","authors":"Johannes Bitzer, Céline Bouchard, János Zatik, Steven Weyers, Terhi Piltonen, Larisa Suturina, Inna Apolikhina, Kristina Gemzell-Danielsson, Maud Jost, Mitchell D Creinin, Jean-Michel Foidart","doi":"10.1080/13625187.2024.2359117","DOIUrl":"10.1080/13625187.2024.2359117","url":null,"abstract":"Purpose: To describe the effects of estetrol (E4) 15 mg/drospirenone (DRSP) 3 mg on physical and emotional premenstrual and menstrual symptoms.Materials and methods: We used Menstrual Distress Questionnaire (MDQ) data from a phase-3 trial (NCT02817828) in Europe and Russia with participants (18 - 50 years) using E4/DRSP for up to 13 cycles. We assessed mean changes in MDQ-t-scores from baseline to end of treatment in premenstrual (4 days before most recent flow) and menstrual (most recent flow) scores for 4 MDQ domains in starters and switchers (use of hormonal contraception in prior 3 months) and performed a shift analysis on individual symptoms within each domain.Results: Of 1,553 treated participants, 1,398(90.0%), including 531(38%) starters, completed both MDQs. Starters reported improvements for premenstrual Pain (-1.4), Water Retention (-3.3) and Negative Affect (-2.5); and for menstrual Pain (-3.5), Water Retention (-3.4), and Negative Affect (-2.7) (all p < 0.01). For switchers, no changes were significant except an increase in premenstrual (+1.0, p = 0.02) and menstrual (+1.5, p = 0.003) Water Retention. We observed a change in symptom intensity in >40% of participants for Cramps, Backache and Fatigue (domain Pain), Painful or Tender Breast and Swelling (domain Water Retention) and Mood Swings and Irritability (domain Negative Affect).Conclusion: E4/DRSP starters experienced significant improvements in the domains Pain, Water Retention and Negative Affect particularly benefiting those with more severe baseline symptoms. Switchers showed minimal changes.","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":" ","pages":"150-159"},"PeriodicalIF":1.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141433270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction of peer-reviewed articles, a difficult but crucial choice: our experience from The European Journal of Contraception & Reproductive Health Care. 撤回经同行评审的文章，一个困难但关键的选择：《欧洲避孕与生殖保健杂志》的经验。

IF 1.7 4区医学

European Journal of Contraception and Reproductive Health Care Pub Date : 2024-06-01 Epub Date: 2024-04-02 DOI: 10.1080/13625187.2024.2333421

Frans Roumen, Giovanni Grandi, Johannes Bitzer

引用次数: 0

Migration of etonogestrel subcutaneous contraceptive implants: systematic review and recommendations for practice. 依托诺孕酮皮下避孕植入物的迁移：系统综述和实践建议。

IF 1.7 4区医学

European Journal of Contraception and Reproductive Health Care Pub Date : 2024-06-01 Epub Date: 2024-05-07 DOI: 10.1080/13625187.2024.2342919

Édith Guilbert, Hélène Arguin, Mathieu Bélanger

{"title":"Migration of etonogestrel subcutaneous contraceptive implants: systematic review and recommendations for practice.","authors":"Édith Guilbert, Hélène Arguin, Mathieu Bélanger","doi":"10.1080/13625187.2024.2342919","DOIUrl":"10.1080/13625187.2024.2342919","url":null,"abstract":"Introduction: Migration is a rare but serious complication of the etonogestrel contraceptive implant, and little is known about its extent.Purpose: To document and characterise cases of etonogestrel contraceptive implant migration in the scientific literature.Methods: A systematic review of Medline, Embase and Global Health databases was carried out between January 2000 and January 2023 to identify articles presenting implant migrations. Narrative reviews, conference abstracts and articles not written in English or French were excluded.Results: Forty-five articles, mostly published since 2016, were identified (eight case series and 37 case reports), for a total of 148 independent cases of migration: in pulmonary blood vessels (n = 74), in non-pulmonary blood vessels (n = 16) and extravascular (n = 58). Many patients are asymptomatic and migration is often an incidental finding. A non-palpable implant and symptoms related to implant location (intra- or extra-vascular) may be indicative of migration. Inadequate insertion and normal or underweight appear to increase the risk of migration. Scientific societies and authors offer practical strategies to deal with implant migration.Conclusion: Professionals who insert and remove contraceptive implants must be adequately trained. They need to be on the lookout for implant migration, and promptly refer patients to appropriate care if migration is suspected.","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":" ","pages":"115-130"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Let's reconsider modern progestin-only pills during isotretinoin and retinoid therapy. 让我们重新考虑异维A酸和维甲酸治疗期间的现代纯孕激素药片。

IF 1.7 4区医学

European Journal of Contraception and Reproductive Health Care Pub Date : 2024-04-01 Epub Date: 2024-03-01 DOI: 10.1080/13625187.2024.2315239

Marco Manfredini, Lucio Di Castri, Giovanni Grandi

引用次数: 0

Minimally invasive transurethral holmium laser surgery for the management of an IUD with bladder migration. 经尿道钬激光微创手术治疗宫内节育器膀胱移位。

IF 1.7 4区医学

European Journal of Contraception and Reproductive Health Care Pub Date : 2024-04-01 Epub Date: 2024-01-29 DOI: 10.1080/13625187.2023.2298357

Dawei Ni, Kun Liu, Mingming Lu, Can Wei, Yanbin Zhang

引用次数: 0

Retraction. 撤回。

IF 1.7 4区医学

European Journal of Contraception and Reproductive Health Care Pub Date : 2024-04-01 Epub Date: 2024-02-16 DOI: 10.1080/13625187.2024.2315914

引用次数: 0

Retraction. 撤回。

IF 1.7 4区医学

European Journal of Contraception and Reproductive Health Care Pub Date : 2024-04-01 Epub Date: 2024-02-16 DOI: 10.1080/13625187.2024.2315912

引用次数: 0

Health benefits of combined oral contraceptives - a narrative review. 复方口服避孕药对健康的益处 - 综述。

IF 1.7 4区医学

European Journal of Contraception and Reproductive Health Care Pub Date : 2024-04-01 Epub Date: 2024-03-01 DOI: 10.1080/13625187.2024.2317295

Herjan J T Coelingh Bennink, Femke A M van Gennip, Mireille G F Gerrits, Jan F M Egberts, Kristina Gemzell-Danielsson, Helena Kopp-Kallner

{"title":"Health benefits of combined oral contraceptives - a narrative review.","authors":"Herjan J T Coelingh Bennink, Femke A M van Gennip, Mireille G F Gerrits, Jan F M Egberts, Kristina Gemzell-Danielsson, Helena Kopp-Kallner","doi":"10.1080/13625187.2024.2317295","DOIUrl":"10.1080/13625187.2024.2317295","url":null,"abstract":"Purpose: This review presents an update of the non-contraceptive health benefits of the combined oral contraceptive pill.Methods: We conducted a literature search for (review) articles that discussed the health benefits of combined oral contraceptives (COCs), in the period from 1980 to 2023.Results: We identified 21 subjective and/or objective health benefits of COCs related to (i) the reproductive tract, (ii) non-gynaecological benign disorders and (iii) malignancies. Reproductive tract benefits are related to menstrual bleeding(including anaemia and toxic shock syndrome), dysmenorrhoea, migraine, premenstrual syndrome (PMS), ovarian cysts, Polycystic Ovary Syndrome (PCOS), androgen related symptoms, ectopic pregnancy, hypoestrogenism, endometriosis and adenomyosis, uterine fibroids and pelvic inflammatory disease (PID). Non-gynaecological benefits are related to benign breast disease, osteoporosis, rheumatoid arthritis, multiple sclerosis, asthma and porphyria. Health benefits of COCs related to cancer are lower risks of endometrial cancer, ovarian cancer and colorectal cancer.Conclusions: The use of combined oral contraceptives is accompanied with a range of health benefits, to be balanced against its side-effects and risks. Several health benefits of COCs are a reason for non-contraceptive COC prescription.","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":" ","pages":"40-52"},"PeriodicalIF":1.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knowledge of non-contraceptive benefits of and willingness to consider taking oral contraceptive pills among a low-risk female population: a cross-sectional study. 一项横断面研究：低风险女性人群对口服避孕药非避孕益处的了解以及考虑服用口服避孕药的意愿。

IF 1.7 4区医学

European Journal of Contraception and Reproductive Health Care Pub Date : 2024-04-01 Epub Date: 2024-01-29 DOI: 10.1080/13625187.2023.2300944

Caitlin Alsandria O'Hara, Teoh Wei Shan, Joseph Ng Soon Yau

{"title":"Knowledge of non-contraceptive benefits of and willingness to consider taking oral contraceptive pills among a low-risk female population: a cross-sectional study.","authors":"Caitlin Alsandria O'Hara, Teoh Wei Shan, Joseph Ng Soon Yau","doi":"10.1080/13625187.2023.2300944","DOIUrl":"10.1080/13625187.2023.2300944","url":null,"abstract":"Background: In addition to its widely-appreciated contraceptive applications, the oral contraceptive pill (OCP) conveys both oncological and non-oncological benefits. Oncological benefits include a decreased risk of endometrial, ovarian, and colorectal cancer. Non-oncological benefits include reducing androgenic effects and alleviating menstruation-related problems. This study aimed to ascertain knowledge levels of non-contraceptive benefits and risks of OCP use among participants without contraindications to OCPs. This study also assessed factors associated with participants being more likely to consider taking OCPs.Methods: 263 women aged 21 to 40 years old with no contraindications for OCP usage participated in this study. An anonymous questionnaire collected sociodemographic information and assessed participants' knowledge of the non-contraceptive benefits and risks associated with OCP use. Multivariate linear regression was used to assess factors associated with knowledge levels. Multivariate logistic regression was used to investigate factors associated with being more likely to consider taking OCPs among women who did not presently take them.Results: Multivariate logistic regression revealed that participants who were more knowledgeable overall about the non-contraceptive benefits of OCPs were more likely to consider taking OCPs (coefficient = 0.184, p-value = 0.00). Knowledge of both oncological and non-oncological benefits of OCP use was relatively poor, especially among older women. Current OCP users were found to be more knowledgeable about their benefits.Conclusions: As women with greater knowledge of non-contraceptive benefits of OCPs are more likely to consider taking them, knowledge gaps regarding OCPs should be filled, so that more women may reap the non-contraceptive benefits of OCPs.","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":" ","pages":"53-60"},"PeriodicalIF":1.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of progestin subdermal implant in the management of adenomyosis: a systematic review. 孕激素皮下植入在子宫腺肌症治疗中的作用：系统综述。

IF 1.7 4区医学

European Journal of Contraception and Reproductive Health Care Pub Date : 2024-04-01 Epub Date: 2024-03-01 DOI: 10.1080/13625187.2024.2314298

G Chene, H Baffet, E Cerruto, E Nohuz, A Agostini

{"title":"The role of progestin subdermal implant in the management of adenomyosis: a systematic review.","authors":"G Chene, H Baffet, E Cerruto, E Nohuz, A Agostini","doi":"10.1080/13625187.2024.2314298","DOIUrl":"10.1080/13625187.2024.2314298","url":null,"abstract":"Purpose: The long-acting reversible contraception progestin subdermal implant (ENG implant) may be effective to improve endometriosis-related symptoms. Since adenomyosis is a histopathological form of endometriosis, we aimed to evaluate the effectiveness of ENG implant in adenomyosis management.Materials and methods: Electronic search in Medline, Scopus, Embase databases and Google Scholar using combinations of the following keywords: Progestin; subdermal implant; Implanon; Nexplanon; Adenomyosis; Endometriosis.Results: Out of 889 articles in the initial database, 5 prospective observational studies were eligible for inclusion in our literature review. Our review involving 152 participants found a significant reduction in pelvic pain and dysmenorrhoea (baseline median VAS score ranged from 10 to 7.62 before implantation vs VAS score ranged from 1.81 to 0.1 after implantation) as well as an increase in the levels of haemoglobin after implantation of the device (from 86 g/L to 129 g/L after implantation). Moreover, the improvement may be sustained throughout the long-term follow-up visits (until 36 months). The most common adverse events were changes in bleeding patterns which were tolerable in most cases.Conclusion: ENG implant may be a relevant and promising medical option in the management of adenomyosis. Nevertheless, randomised controlled trials and prospective studies with larger cohorts are needed to confirm the potential role of ENG implant in the management of adenomyosis.","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":" ","pages":"61-68"},"PeriodicalIF":1.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0